Brandenberg et al., Predicting HIV-1 antibody neutralization in vivo
Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. PLoS Pathogens Brandenberg et al. experimentally determined molecular parameters of the HIV-1 envelope trimer – broadly neutralizing antibody interaction, and subsequently devised a mathematical model of HIV-1 infection and antibody neutralization in vivo. The reason for this work was that the potential of […]
Podlekareva et al., Mortality in HIV patients with susceptible tuberculosis
One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. AIDS Podlekareva et al. on behalf of the TB:HIV Study writing Group aimed to assess and compare mortality rates of HIV patients with drug susceptible tuberculosis (TB) across regions and identify risk factors […]
Sabin et al., Abacavir et le risque de crises cardiaques
Abacavir et le risque de crises cardiaques. BMC Medicine Le médicament anti-VIH Abacavir est fréquemment prescrit aux séropositifs en combinaisons avec d’autres médicaments anti-VIH. Les résultats de diverses études laissent supposer que la prise d’Abacavir augmente le risque de crises cardiaques. Selon les données dont nous disposons actuellement il n’est pas évident s’il s’agit […]
Sabin et al., Abacavir e rischio di malattia cardiovascolare
Abacavir e rischio di malattia cardiovascolare. BMC Medicine Il medicamento anti-HIV abacavir è prescritto molto frequentemente alle persone sieropositive in combinazione con altri farmaci anti-HIV. I risultati di vari studi fanno supporre che l’assunzione di abacavir potrebbe aumentare il rischio di malattie cardiovascolari. In base ai dati disponibili attualmente, non è ancora evidente se […]
Sabin et al., Abacavir und das Risiko für Herzinfarkte
Abacavir und das Risiko für Herzinfarkte. BMC Medicine Das HIV-Medikament Abacavir wird bei HIV-infizierten Personen in Kombination mit anderen HIV-Medikamenten häufig in der HIV-Therapie eingesetzt. Die Resultate von verschiedenen Studien lassen darauf schliessen, dass die Einnahme von Abacavir zu einem erhöhten Risiko für Herzinfarkte führt. Aufgrund der aktuellen Datenlage ist allerdings nicht ganz klar, […]
Casadellà et al., HIV tropism & AIDS progression
Plasma HIV-1 tropism and the risk of short-term clinical progression to AIDS or death. PLoS One Casadellà et al. on behalf of EuroSIDA aimed to investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical progression and death in routine clinical management. In this nested case-control study, cases were subjects with […]
Lifson et al., Improved QOL with immediate ART in START
Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS Lifson et al. on behalf of the INSIGHT Start Study Group assessed if immediate compared to deferred initiation of antiretroviral therapy (ART) in healthy persons living with HIV had a more favorable impact on health-related quality of […]
Borges et al., Fractures and osteonecrosis during HIV
Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clinical Infectious Disease Borges et al. on behalf of EuroSIDA aimed to study the association of exposure to antiretroviral drugs with incident fractures and osteonecrosis of the femoral head and to determine factors independently associated with these two bone outcomes. Among 11’820 included […]
Kovari et al., VHC et le risque de décéder d’une maladie non causée par le foie
L’infection par le virus de l’hépatite C et le risque de décéder d’une maladie non causée par le foie chez les séropositifs de l’Etude suisse de cohorte VIH. Clinical Infectious Diseases Une infection par le virus de l’hépatite C (VHC) chez les séropositifs est fréquente et concerne jusqu’à 30% des séropositifs. L’infection chronique par le […]
Kovari et al., HCV e rischio di morire di una malattia indipendente dal fegato
Epatite C e rischio di morire di una malattia indipendente dal fegato nelle persone sieropositive: studio svizzero della coorte HIV. Clinical Infectious Diseases L’infezione da virus dell’epatite C (HCV) nei sieropositivi è frequente e concerne circa il 30% di loro. L’infezione cronica da HCV è associata a numerose malattie indipendenti dal fegato come ad […]